To evaluate the expression of SOX4 in laryngeal squamous cell carcinoma (LSCC) and its clinical relevance, and to clarify its impact on tumor behavior and underlying molecular mechanisms.
Key Findings:
SOX4 is upregulated in LSCC and correlates with disease progression and lymph node metastasis.
Knockdown of SOX4 inhibits proliferation, migration, and invasion of LSCC cells.
Overexpression of SOX4 promotes a malignant phenotype.
PTBP2 is identified as a downstream effector of SOX4.
The SOX4/PTBP2 axis is linked to tumor immune microenvironment and drug sensitivity.
In vivo knockdown of SOX4 or erlotinib treatment significantly inhibits tumor growth and lymph node metastasis.
Interpretation:
The findings suggest that SOX4 plays a critical role in promoting LSCC progression and metastasis through the regulation of PTBP2, indicating potential therapeutic targets.
Limitations:
The study primarily relies on bioinformatics and in vitro models, which may not fully replicate in vivo conditions.
Further clinical studies are needed to validate the findings and explore therapeutic implications.
Conclusion:
The SOX4-PTBP2 axis may serve as a potential diagnostic and therapeutic target for LSCC.
